UniProt Q9Y572 · PDB · AlphaFold · Substrate: MBP · Clone: full-lengthhigh-confidence target
Top inhibitors
| # | Drug | Inhibition | Residual | KISS | Gini |
|---|---|---|---|---|---|
| 1 | Dabrafenib | 96.0% | 4.0% | 94.74 | 0.633 |
| 2 | Cabozantinib | 94.5% | 5.5% | 92.73 | 0.751 |
| 3 | Vemurafenib | 94.5% | 5.5% | 96.49 | 0.598 |
| 4 | Ibrutinib | 92.9% | 7.1% | 94.74 | 0.723 |
| 5 | Dasatinib | 92.5% | 7.5% | 87.97 | 0.699 |
| 6 | Regorafenib | 91.9% | 8.1% | 95.99 | 0.719 |
| 7 | Lenvatinib | 90.6% | 9.4% | 97.74 | 0.726 |
| 8 | Pazopanib | 82.2% | 17.8% | 97.49 | 0.672 |
| 9 | Encorafenib | 76.6% | 23.4% | 98.50 | 0.755 |
| 10 | Gefitinib | 71.4% | 28.6% | 99.25 | 0.650 |
| 11 | Nilotinib | 65.6% | 34.4% | 96.49 | 0.765 |
| 12 | Lapatinib | 52.5% | 47.5% | 99.25 | 0.616 |
| 13 | Dacomitinib | 47.4% | 52.6% | 97.99 | 0.664 |
| 14 | Gilteritinib | 39.4% | 60.6% | 88.97 | 0.506 |
| 15 | Vandetanib | 39.2% | 60.8% | 95.74 | 0.723 |
| 16 | Axitinib | 25.5% | 74.5% | 93.23 | 0.688 |
| 17 | Bosutinib | 18.5% | 81.5% | 87.22 | 0.555 |
| 18 | Nintedanib | 16.4% | 83.6% | 90.23 | 0.608 |
| 19 | Netarsudil | 12.0% | 88.0% | 93.22 | 0.676 |
| 20 | Sunitinib | 11.6% | 88.4% | 91.73 | 0.524 |
Paralog block
No paralog group registered for this kinase.
EMT expression
- Mesenchymal log2(TPM+1): 0.37
- Epithelial log2(TPM+1): 1.37
- Fold change: -1.00
- Status: No significant change
High-confidence drugs
- Regorafenib — inh 91.9% · KISS 42.19
- Lenvatinib — inh 90.6% · KISS 41.59
- Ibrutinib — inh 92.9% · KISS 41.28
Selectivity landscape vs inhibition on RIPK3
Each point is one of the 92 approved drugs; color = inhibition % on RIPK3.
3D structure
Embedded NGL viewer pulls a representative PDB entry (or AlphaFold model if no experimental structure is registered). Heavy bundle — loaded only on demand.
Annotations
Sign in to read and post annotations.
Loading…